{"id":"oltipraz-1-90mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL178459","moleculeType":"Small molecule","molecularWeight":"226.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oltipraz acts as a potent inducer of NAD(P)H quinone oxidoreductase (NQO1) and glutathione S-transferases (GSTs), which are phase II detoxification enzymes. By upregulating these protective pathways, it increases the body's ability to neutralize and eliminate carcinogenic and toxic compounds, thereby reducing cancer risk and oxidative damage.","oneSentence":"Oltipraz is an organosulfur compound that induces phase II detoxification enzymes and antioxidant pathways, enhancing cellular defense against oxidative stress and carcinogens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:06.676Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer chemoprevention in high-risk populations"},{"name":"Aflatoxin-induced hepatocellular carcinoma prevention"}]},"trialDetails":[{"nctId":"NCT02068339","phase":"PHASE3","title":"Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis","status":"COMPLETED","sponsor":"PharmaKing","startDate":"2014-02","conditions":"Non-alcholic Fatty Liver Disease","enrollment":283}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oltipraz 1 (90mg)","genericName":"Oltipraz 1 (90mg)","companyName":"PharmaKing","companyId":"pharmaking","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oltipraz 1 (90mg) is being studied for its efficacy and safety in reducing liver fat in patients with non-alcoholic fatty liver disease, except for those with liver cirrhosis. This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 clinical trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}